Adverse Drug Reaction Classification System

ADR Ontology
ADR Term Progressive supranuclear palsy
ADR ID BADD_A07602
ADR Hierarchy
17      Nervous system disorders
17.03      Mental impairment disorders
17.03.01      Dementia (excl Alzheimer's type)
17.03.01.002      Progressive supranuclear palsy
Description A degenerative disease of the central nervous system characterized by balance difficulties; OCULAR MOTILITY DISORDERS (supranuclear ophthalmoplegia); DYSARTHRIA; swallowing difficulties; and axial DYSTONIA. Onset is usually in the fifth decade and disease progression occurs over several years. Pathologic findings include neurofibrillary degeneration and neuronal loss in the dorsal MESENCEPHALON; SUBTHALAMIC NUCLEUS; RED NUCLEUS; pallidum; dentate nucleus; and vestibular nuclei. (From Adams et al., Principles of Neurology, 6th ed, pp1076-7) [MeSH]
MedDRA Code 10036813
MeSH ID D013494
ADR Severity Grade (FAERS)
ADR Severity Grade (CTCAE) Not Available
Synonym
Progressive supranuclear palsy | Steele-Richardson-Olszewski syndrome | Supranuclear Palsy, Progressive | Progressive Supranuclear Palsies | Supranuclear Palsies, Progressive | Palsy, Progressive Supranuclear | Progressive Supranuclear Ophthalmoplegia | Progressive Supranuclear Palsy | Steele-Richardson-Olszewski Disease | Steele Richardson Olszewski Disease | Steele-Richardson-Olszewski Syndrome | Steele Richardson Olszewski Syndrome | Syndrome, Steele-Richardson-Olszewski | Supranuclear Palsy, Progressive, 1 | Ophthalmoplegia, Progressive Supranuclear | Supranuclear Ophthalmoplegia, Progressive | Richardson's Syndrome | Richardson Syndrome | Syndrome, Richardson's
Drugs Leading to the ADR
Drug IDDrug NameADR Frequency (FAERS)ADR Severity Grade (FAERS)
BADD_D01442Metoclopramide0.000431%
BADD_D01599Olanzapine0.000210%
BADD_D01951Risperidone0.000485%
BADD_D02392Zoledronic acid--
BADD_D02451Pimavanserin0.000131%
The 1th Page    1    Total 1 Pages